Browse CMTM6

Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Early endosome membrane Multi-pass membrane protein Recycling endosome membrane Multi-pass membrane protein Note=Co-localizes with PD-L1/CD274 in the plasma membrane and in recycling endosomes.
Domain PF01284 Membrane-associating domain
Function

Master regulator of recycling and plasma membrane expression of PD-L1/CD274, an immune inhibitory ligand critical for immune tolerance to self and antitumor immunity. Associates with both constitutive and IFNG-induced PD-L1/CD274 at recycling endosomes, where it protects PD-L1/CD274 from being targeted for lysosomal degradation, likely by preventing its STUB1-mediated ubiquitination. May stabilize PD-L1/CD274 expression on antigen presenting cells and potentiates inhibitory signaling by PDCD1/CD279, its receptor on T-cells, ultimately triggering T-cell anergy.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0005125 cytokine activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CMTM6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CMTM6 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28813417MelanomaInhibit immunityCMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degradation. CMTM6 depletion, via the reduction of PD-L1, significantly alleviates the suppression of tumour-specific T cell activity in vitro and in vivo.
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CMTM6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.8 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CMTM6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0280.909
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0670.98
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1030.956
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1880.681
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1810.913
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1950.924
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0440.926
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0160.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1340.953
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0270.985
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4170.849
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1210.2
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CMTM6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CMTM6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CMTM6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CMTM6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CMTM6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CMTM6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CMTM6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCMTM6
NameCKLF-like MARVEL transmembrane domain containing 6
Aliases FLJ20396; CKLFSF6; chemokine-like factor super family 6; chemokine-like factor superfamily 6; PRO2219; chemo ......
Chromosomal Location3p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CMTM6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.